SCPH•benzinga•
scPharmaceuticals Announces FDA Approval For Supplemental New Drug Application Expanding FUROSCIX Indication To Include Treatment Of Edema In Patients With Chronic Kidney Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga